Molecular targeted therapy for non-small cell lung cancer has significantly improved clinical outcomes in patients with driver gene-positive tumors.Nevertheless,treatment-related adverse drug reactions(ADRs)present challenges to patients'quality of life and treatment adherence.Given the broad clinical utilization of various targeted agents,it is imperative to comprehensively characterize and standardize the management of these ADRs.This review systematically synthesizes the common and unique spectra of ADRs associated with inhibitors targeting multiple pathways,including the epidermal growth factor receptor,encompassing dermatologic toxicities,diarrhea,hepatotoxicity,and interstitial lung disease.It also discusses the potential role of predictive biomarkers in identifying high-risk populations to facilitate early risk stratification.Furthermore,based on current evidence-based medicine and authoritative clinical guidelines,this work highlighted a multidisciplinary management strategy,tailored according to severity grading,which includes dose modification or treatment interruption,symptomatic and supportive care,as well as lifestyle interventions.Through a deepened understanding,proactive monitoring,and standardized management of ADRs,the aim is to maximize treatment benefits while minimizing therapy-related toxic burden.

Molecular targeted therapy for non-small cell lung cancer has significantly improved clinical outcomes in patients with driver gene-positive tumors.Nevertheless,treatment-related adverse drug reactions(ADRs)present challenges to patients'quality of life and treatment adherence.Given the broad clinical utilization of various targeted agents,it is imperative to comprehensively characterize and standardize the management of these ADRs.This review systematically synthesizes the common and unique spectra of ADRs associated with inhibitors targeting multiple pathways,including the epidermal growth factor receptor,encompassing dermatologic toxicities,diarrhea,hepatotoxicity,and interstitial lung disease.It also discusses the potential role of predictive biomarkers in identifying high-risk populations to facilitate early risk stratification.Furthermore,based on current evidence-based medicine and authoritative clinical guidelines,this work highlighted a multidisciplinary management strategy,tailored according to severity grading,which includes dose modification or treatment interruption,symptomatic and supportive care,as well as lifestyle interventions.Through a deepened understanding,proactive monitoring,and standardized management of ADRs,the aim is to maximize treatment benefits while minimizing therapy-related toxic burden.